The shares of Bristol-Myers Squibb Company have decreased by more than -4.29% this year alone. The shares recently went down by -0.32% or -$0.19 and now trades at $58.65. The shares of Petroleo Brasileiro S.A. – Petrobras (NYSE:PBR-A), has jumped by 26.04% year to date as of 04/13/2018. The shares currently trade at $12.39 and have been able to report a change of -1.90% over the past one week.

The stock of Bristol-Myers Squibb Company and Petroleo Brasileiro S.A. – Petrobras were two of the most active stocks on Friday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

**Next 5Y EPS Growth: 11.87% versus 5.30%**

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that BMY will grow it’s earning at a 11.87% annual rate in the next 5 years. This is in contrast to PBR-A which will have a positive growth at a 5.30% annual rate. This means that the higher growth rate of BMY implies a greater potential for capital appreciation over the years.

**Profitability and Returns**

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. BMY has an EBITDA margin of 28.49%, this implies that the underlying business of BMY is more profitable. These figures suggest that BMY ventures generate a higher ROI than that of PBR-A.

**Valuation**

BMY currently trades at a forward P/E of 15.33, a P/B of 8.17, and a P/S of 4.63 while PBR-A trades at a forward P/E of 8.73, a P/B of 1.03, and a P/S of 0.96. This means that looking at the earnings, book values and sales basis, PBR-A is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

**Analyst Price Targets and Opinions**

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of BMY is currently at a -10.46% to its one-year price target of 65.50. Looking at its rival pricing, PBR-A is at a -6.35% relative to its price target of 13.23.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), BMY is given a 2.60 while 2.60 placed for PBR-A. This means that analysts are equally bullish on their outlook for the two stocks stocks.

**Insider Activity and Investor Sentiment**

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for BMY is 1.41 while that of PBR-A is just 1.52. This means that analysts are more bullish on the forecast for BMY stock.

Conclusion

The stock of Petroleo Brasileiro S.A. – Petrobras defeats that of Bristol-Myers Squibb Company when the two are compared, with PBR-A taking 5 out of the total factors that were been considered. PBR-A happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, PBR-A is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for PBR-A is better on when it is viewed on short interest.